Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Nurix Therapeutics Inc
NRIXCurrent price
22.92 USD
-3.58 USD (-13.51%)
Last closed
26.86 USD
Company
www.nurixtx.com
ISIN
US67080M1036
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
1 936 664 576 USD
Yield for 12 month
+277.59 %
1Y
3Y
5Y
10Y
15Y
NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. Address: 1700 Owens Street, San Francisco, CA, United States, 94158
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
31.2 USDP/E ratio
–Dividend Yield
–Current Year
+76 987 000 USD
Last Year
+38 627 000 USD
Current Quarter
+12 588 000 USD
Last Quarter
+12 092 000 USD
Current Year
+63 333 000 USD
Last Year
+38 627 000 USD
Current Quarter
+8 442 000 USD
Last Quarter
+8 001 000 USD
Key Figures NRIX
1 year
3 years
5 years
10 years
EBITDA
-186 400 992 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-29.46 %
PEG Ratio
–
Return On Equity TTM
-57.96 %
Wall Street Target Price
31.2 USD
Revenue TTM
56 424 000 USD
Book Value
5.62 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-31.8 %
Dividend Yield
–
Gross Profit TTM
-145 870 000 USD
Earnings per share
-2.9 USD
Diluted Eps TTM
-2.9 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics NRIX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NRIX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation NRIX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
26.8637
Price Sales TTM
34.3234
Enterprise Value EBITDA
-3.3455
Price Book MRQ
5.139
Financials NRIX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NRIX
For 52 weeks
5.65 USD
29.56 USD
50 Day MA
24.35 USD
Shares Short Prior Month
9 077 737
200 Day MA
18.21 USD
Short Ratio
11.3
Shares Short
9 240 563
Short Percent
14 %
BeatStart